Bridging the gap in PROTAC development

Targeted protein degradation is redefining drug discovery by offering a way to eliminate disease-causing proteins once considered 'undruggable'. By hijacking the cell’s natural ubiquitin-proteasome system (UPS), technologies like PROTACs and molecular glues enable selective degradation of proteins lacking traditional binding sites. Yet, challenges such as poor solubility, limited cell permeability, and off-target effects continue to hinder progress.

Discover how ChemPartner’s UPS Assay Platform addresses these barriers by interrogating 11 key steps, ensuring every step of the degradation pathway is investigated.